Trial reportJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2018
Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker.
Trial report in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 8 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- A meta analysis of pulmonary vein isolation compared with additional ablation strategies for atrial fibrillation.BMC cardiovascular disorders · 2025Pooled it
- Effect of Combined Renal Denervation and Pulmonary Vein Isolation on Atrial Fibrillation: A Systematic Meta-Analysis.Anatolian journal of cardiology · 2025Pooled it
- Pooled it
- Pulmonary vein isolation plus adjunctive therapy for the treatment of atrial fibrillation: a systematic review and meta-analysis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024Pooled it
- Renal denervation for atrial fibrillation: a comprehensive updated systematic review and meta-analysis.Journal of human hypertension · 2022Pooled it
- Systematic review of renal denervation for the management of cardiac arrhythmias.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Pooled it
- Comparing efficacy and safety in catheter ablation strategies for atrial fibrillation: a network meta-analysis.BMC medicine · 2022Pooled it
- Renal sympathetic denervation in addition to pulmonary vein isolation reduces the recurrence rate of atrial fibrillation: an updated meta-analysis of randomized control trials.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2021Pooled it
- Review
- Efficacy of renal denervation as an adjunct to pulmonary vein isolation for atrial fibrillation treatment: a systematic review and meta-analysis.European heart journal open · 2024Article
- Emerging Role of Renal Sympathetic Denervation as an Adjunct Therapy to Atrial Fibrillation Ablation.Reviews in cardiovascular medicine · 2024Review
- Renal denervation in the antihypertensive arsenal - knowns and known unknowns.Journal of hypertension · 2022Article
- The Heart Brain Team and Patient-Centered Management of Ischemic Stroke.JACC. Advances · 2022Review
- Comparing Efficacy and Safety in Catheter Ablation Strategies for Paroxysmal Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials.Diagnostics (Basel, Switzerland) · 2022Review
- Renal arteries denervation: from the treatment of resistant hypertension to the treatment of atrial fibrillation.European heart journal supplements : journal of the European Society of Cardiology · 2021Article
- Neuroscientific therapies for atrial fibrillation.Cardiovascular research · 2021Review
- Renal denervation: can we press the "ON" button again in 2020?Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2020Review
- Efficacy and safety of renal denervation in addition to pulmonary vein isolation for atrial fibrillation and hypertension-Systematic review and meta-analysis of randomized controlled trials.Journal of arrhythmia · 2020Article
- Effects of renal denervation on 24-h heart rate and heart rate variability in resistant hypertension.Clinical research in cardiology : official journal of the German Cardiac Society · 2020Article
- Neuromodulation for the Treatment of Heart Rhythm Disorders.JACC. Basic to translational science · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundAtrial fibrillation (AF) commonly occurs in chronic kidney disease (CKD), occasioning adverse outcomes. Merging pulmonary vein isolation (PVI) and renal sympathetic denervation (RSD) may decrease the recurrence of AF in subjects with CKD and uncontrolled hypertension. We considered that RSD could reduce the recurrence of AF in patients with CKD by modulating sympathetic hyperactivity. We aimed to evaluate the impact of RSD or spironolactone 50 mg/day associated with PVI in reducing systolic blood pressure (BP), AF recurrence, and AF burden in patients with a history of paroxysmal AF and mild CKD.
methodsThis was a single-center, prospective, longitudinal, randomized, double-blind study. The individuals were randomly divided into two groups (PVI + spironolactone, n = 36, and PVI + RSD, n = 33). All of them were followed for exactly 1 year to assess maintenance of sinus rhythm and to monitor the other variables.
resultsAmbulatory BP measurements were reduced in both groups and at the 12th month also differed between groups. Significantly more patients in the PVI + RSD (61%) than in the PVI + spironolactone group (36%) were AF-free at the 12th month of follow-up, P = 0.0242. Toward the end of the study, the mean AF burden was lower in the PVI + RSD group as compared to PVI + spironolactone group, at the 9th month: ∆ = - 10% (P < 0.0001), and at the 12th month: ∆ = - 12% (P < 0.0001), respectively.
conclusionsPVI + RSD is safe and appears to be superior to PVI + spironolactone in BP reduction, augmentation of AF event-free rate, reduction of AF burden, and improvement of renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.